Drug Box 3 Flashcards

1
Q

Esmolol Name

A

Generic (Esmolol), Trade (Brevibloc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Esmolol Classification

A

Cardioselective Beta Blocker/B-1 adrengeric receptor antagonist, Class II anti-arrhythmic agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Esmolol Contraindication

A

Use esmolol with caution in patients with asthma; chronic obstructive pulmonary disease; atrioventricular heart block, or cardiac failure not caused by tachycardia; and diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Esmolol Dose and route

A

SVT>loading:50 to 200 mcg/kg/min for 1 minute; follow by infusion of 50 mcg/kg/min for 4 minutes. If the desired effect is not achieved, repeat loading dose and increase infusion to 100 mcg/kg/min. May repeat the process up to a maximum of 300 mcg/kg/min. (Nagelhout handbook, pg 636)
- Loading dose: 50-300 mg/kg/min (Flood, pg 479 table)
- Single IV push- 5-10 mg (Dr. Hammons)
-10-80 mg IV (Flood, pg. 479 table)
Dosage forms:
10mg/mL in 10-mL vial for direct intravenous injection; 250 mg/mL in 10-mL ampule for intravenous infusion. Only administered IV. (Nagelhout handbook, pg 636)
Route IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Esmolol MOA

A

By blocking adrengeric activity of epi and norepi, it decreases inotropic contractility, heart rate, and conduction. Esmolol increases atrioventricular refractory time decreases oxygen demand of the myocardium, and decreases atrioventricular conduction. A minor Beta 2 blockade has been reported with high IV infusion doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Esmolol Onset

A

1-2 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Esmolol Peak

A

5-6 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Esmolol Duration

A

10-20 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Labetalol Name

A

Trandate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Labetalol Classification

A

Combined α- and β-Adrenergic Receptor Antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Labetalol Contraindications

A

bronchial asthma, 2nd-3rd degree heart block, hepatic failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Labetalol Dose and route

A

Dose – IV: 0.1 - 0.5 mg/kg (Start with 5-10 mg)
Oral: 100-600 mg BID (Flood, p. 489)
5.) Route – IV, Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Labetalol MOA

A

exhibits selective α1 and non-selective β1- and β2-adrenergic antagonist effects. Presynaptic α2 receptors are spared by labetalol such that released norepinephrine can continue to inhibit further release of catecholamines via the negative feedback mechanism resulting from stimulation of α2 receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Labetalol Elimination

A

metabolized by conjugation of glucuronic acid (enzyme that helps metabolize
drugs), with 5% of drug recovered in urine (Flood, p. 489)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Labetalol Onset

A

iv 1-3 min

oral 20-40 mins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Labetalol Peak

A

5-15min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Labetalol Duration

A

iv- 20mins- 2 hrs

oral- 4-12 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Labetalol Misc

A

chronic bronchitis, emphysema, pre existing peripheral vascular disease, pheochromocytoma, and diabetes. It is contraindicated in bronchial asthma, overt heart failure, greater than first degree heart block, and hepatic failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Metoprolol Name

A

Lopresor, Toprol XL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Metoprolol Classification

A

Beta-Blocker, Beta-1 Selective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Metoprolol Contraindication

A

COPD, CAD, Vulnerable to hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Metoprolol Dose and Route

A

Dose: Oral 50-400mg (Flood p. 479). Extended Release 50-150mg (Flood p.480) IV 1mg-15mg (Flood, p.479)
Route: PO or IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Metoprolol MOA

A

Selective B1-Adrenergic receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Metoprolol Elimination

A

Absorbed from the gastrointestinal tract offset by sustabial hepatic first-pass-metabolism, only 40% of drug reaches systemic circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Metoprolol Onset

A

1-5 mins iv

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Metoprolol Peak

A

iv- 20 mins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Metoprolol Duration

A

iv 5-7 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Metoprolol Misc

A

Selectivity is dose related and large doses become non-selective antagonist B2 receptor as well as B1. (Flood p. 482)

Supply: 5mg/5ml or 1mg/ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Neostigmine Name

A

Prostigmine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Neostigmine Classification

A

Anticholinesterase agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Neostigmine Contraindications

A

Use with caution in patients with bradycardia, bronchial asthma, epilepsy, cardiac arrhythmias, peptic ulcer, peritonitis, or mechanical obstruction of the intestines or urinary tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Neostigmine Dose and Route

A

Dose : 60 to 80 µg/kg (maximum 5mg)[dose cited from Flood, ignore other sources]
Myasthenia gravis PO 15-375 mg daily; IM 0.5-2 mg (Nagelhout Handbook P. 671)
maximum effective dose is in the 60 to 80 µg/kg range (Flood, 2016 P.335)
Dose range 25-75 mcg/kg (Nagelhout, 2018p.162)
5.) Route IV for reversal, IM or PO for myasthenia gravis (Nagelhout Handbook Page 671)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Neostigmine MOA

A

Mechanism of Action (MOA): It inhibits AChE by forming a drug-enzyme complex that degrades in the same manner as ACh-Cholinesterase complex, thereby increasing the concentration of endogenous ACh around the cholinoreceptors (Nagelhout hard copy textbook page 162 para 2). The ACh that accumulates at the NMJ competes with the residual molecules of NMBD for the available unoccupied nicotinic ACh receptors at the NMJ. (Flood hard copy textbook, P.334 last paragraph).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Neostigmine Elimination

A

Renal excretion accounts for about 50% of the excretion of neostigmine . Renal failure decreases the plasma clearance of neostigmine as much as, if not more than, that of the long-acting neuromuscular blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Neostigmine Onest

A

3-15 mins

36
Q

Neostigmine Duration

A

0.4-4 hrs

37
Q

Neostigmine Misc

A

Has a ceiling effect once inhibition of AChE is complete as evidenced by 4 twitches on TOF. (Flood, 2016 P.335).
May increase PONV
To minimize the muscarinic cardiovascular side effects of acetylcholinesterase inhibitors, give with glycopyrrolate (7 to 15 µg/kg) which matches the slower acting neostigmine (40 to 70 µg/kg) (Flood, 2016 P.335).
Overdose may induce a cholinergic crisis characterized by; n&v, bradycardia/tachycardia, excessive salivation, sweating, bronchospasm, weakness and paralysis. Treated by discontinuing neostigmine and administration of atropine(Flood, 2016 P.335

38
Q

Robinul Name

A

Glycopyrrolate

39
Q

Robinul Classification

A

Anticholinergic

40
Q

Robinul Contraindication

A

Peptic Ulcer Disease, glaucoma, obstructive uropathy, GI disease. Mitral stenosis and cardiovascular instability in acute hemorrhage. Myasthenia gravis.

41
Q

Robinul Dose and Route

A

4.) Dose - 10-20 mcg/kg or 0.1 - 0.2 mg (Nagelhout pg. 180, 198) (7-15 mcg/kg) - Hammon PPT
Pediatrics - 0.01 mg IV (pg. 1199, nagelhout)
5.) Route - IV, IM, inhalation - Nagelhout pg. 180,198

42
Q

Robinul MOA

A

Synthetic quaternary ammonium compound that is an anticholinergic and blocks the effects of acetylcholines at parasympathetic sites. Reduces the rate of salivation by preventing the stimulation of acetylcholine receptors.

43
Q

Robinul Elimination

A

feces (15%) and urine (85%) within 48 hours

44
Q

Robinul Onset

A

Onset - 1-2 minutes IV. 15-30 minutes IM/SQ

45
Q

Robinul Peak

A

30-45 min

46
Q

Robinul Duration

A

2-4 hrs

47
Q

Robinul Misc

A
  • F/M Ratio of 0.13 (Value less than 1 represents incomplete transfer to fetal circulation.) Does not pass the placental barrier. Insoluble in lipids. Effective bronchodilator, but not a popular therapy of obstructive airway diseases. Mild decrease in gastric hydrogen ion secretion. Moderate relaxation of smooth muscle. Lower esophageal sphincter relaxation. Moderate antisialagogue. Moderate increase in heart rate (Less than Atropine). Less initial tachycardia than atropine; no central nervous system effects (does not pass the blood-brain barrier). Fewer systemic side effects than atropine. Onset time of glycopyrrolate and neostigmine are closely matched (used together because it is slower acting and lasts longer than atropine).

Supply: 0.2mg/ml

48
Q

Zofran Name

A

Ondansetron

49
Q

Zofran Classification

A

serotonin receptor 5HT3 antagonist

50
Q

Zofran Contraindication

A

Use with caution in
o pregnant or nursing women
o Children younger than three years
o All patients with known hypersensitivity

51
Q

Zofran Dose and Route

A

Ondansetron, 4 to 8 mg IV over 2 to 5 minutes immediately before induction (flood 697)
o Pediatric (flood 697)
§ Oral (0.15 mg/ kg)
§ IV (0.05 to 0.15 mg/kg)
§ For preadolescent children undergoing ambulatory surgery

52
Q

Zofran MOA

A

Ondansetron is a carbazalone derivative that is structurally related to serotonin and possesses specific 5-HT3 subtype receptor antagonist properties.

53
Q

Zofran Elimination

A

predominantly in liver e

54
Q

Zofran Onset

A

30-60 min

55
Q

Zofran Peak

A

1-1.5 hrs

56
Q

Zofran Duration

A

12-24 hr

57
Q

Zofran Misc

A

4mg/ml

58
Q

Toradol Name

A

Sprix

59
Q

Toradol Classification

A

NSAID

60
Q

Toradol Dose and Route

A

Dose
IV/IM: 30 mg - 60 mg (not to exceed 120 mg/day)
Route
PO, IV, IM, intrathecal, and intranasal

61
Q

Toradol MOA

A

Inhibits prostaglandin synthesis producine peripherally mediated analgesia

62
Q

Toradol Elimination

A

Primarily metabolized by liver but mainly excreted from kidneys

63
Q

Toradol Onset

A

30 mins

64
Q

Toradol Peak

A

iv/im 1-2 hrs 2=3 hr PO

65
Q

Toradol Duration

A

4-6 hrs

66
Q

Toradol Contraindcations

A

Avoid giving to orthopedic patients during 1 week post-op if possible, because it can delay bone healing.

67
Q

Toradol Misc

A

S/S: stroke, MI, GI bleeding, Stevens-Johnson Syndrome

68
Q

Decadron Name

A

Dexamethasone sodium phosphate

69
Q

Decadron Classification

A

long acting corticosteroid

70
Q

Decadron Contraindication

A

Patients with peptic ulcers, osteoporosis, psychosis, psychoneurosis, acute bacterial infections, herpes zoster, herpes simplex ulceration of the eye, and other viral infections. Use it with caution in patients with DM, chronic renal failure, or infection disease in elderly patients. May increase the risk of developing TB in patients with purified protein derivative test. They may increase the risk of development of serious or fatal infection in person exposed to viral illness such as chickenpox.

71
Q

Decadron Dose and Route

A
  1. Dose: Adult- Initial 0.5-9 mg IM or IV daily dependent upon the disease treated. See Nagelhout p. 625 for disease specific dosing. Children: intramuscular or intravenous push: 6 to 40mcg/kg. Must be administered slowly 3-5 minutes IV.
  2. Route: Oral, topical, IV, IM, IA
72
Q

Decadron MOA

A

For PONV mechanism of action is unclear (Nagelhout p.195). Steroids inhibit the production of prostaglandins and therefore reduce pain (Nagelhout p.116)

73
Q

Decadron Onset

A

IV/IM within 10-30 minutes, inhalation within 20 minutes (Nagelhout handbook p.625)

74
Q

Decadron Peak

A

Peak: Oral 1-2 hours, IM ~30 to 120, IV 5 to 10 mins

75
Q

Decadron Duration

A

Duration: Oral, topical, IV, IM, IA 36-54 hours (Flood p. 276)

76
Q

Decadron Misc

A

Management of PONV, the mechanism of action is unclear. Chosen to treat certain types of cerebral edema (Flood, p. 694). Dexamethasone is 25 times stronger than endogenous cortisol (Flood, p.276, table 9-13). Prolongs the analgesia form interscalene blocks using ropivacaine or bupivacaine
supply: 4mg/ml

77
Q

Sugammadex Name

A

Bridion

78
Q

Sugammadex Classification

A

modified (gamma)y-cyclodextrin; selective neuromuscular blockade reversal agent.

79
Q

Sugammadex Contraindication

A

renal impairment – creatinine clearance <30 ml/min (Flood p.338), allergy, bleeding;

80
Q

Sugammadex Dose and Route

A
  1. ) Dose 2-16mg/kg ; for TOF(train of four) 2 then 2mg/kg, 4mg/kg for deeper block at 1-2 post tetanic count. More profound block would require range of 8-16mg/kg (Flood, pp. 338-339).
  2. ) Route IV over 10 seconds(Bridion pamphlet from drug rep see Dr. Hammon)
81
Q

Sugammadex MOA

A

encapsulates/binds to steroidal neuromuscular blocking drugs (rocuronium, vecuronium, and pancuronium)

82
Q

Sugammadex Elimination

A

mainly kidneys; approx.. 70% excreted within 6 hours, >90% within 24 hour

83
Q

Sugammadex Onset

A

3 mins

84
Q

Sugammadex Peak

A

with in 3 mins

85
Q

Sugammadex Duration

A

2 hrs with normal renal function

86
Q

Sugammadex Misc

A

Does not affect acetylcholinesterase, eliminating the need for the co-administration of an anticholinergic (Flood, pp. 337)
Does NOT work on: succinylcholine benzylisoquinolinium neuro-muslcular blockers – mivacurium, atracurium, and cisatracurium (Flood, pp.339)
If on birth control, must use non-steroidal method of contraception for at least 7 days(Nagelhout, pp.164)
Only works on rocuronium, vecuronium, and pancuronium